Wolverine Trading
GALT icon

Wolverine Trading’s Galectin Therapeutics GALT Stock Holding History

Wolverine Trading’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$76K Buy
18,000
+6,900
+62% +$26K ﹤0.01% 5299
2025
Q2 		$25.9K Sell
11,100
-2,600
-19% -$3.89K ﹤0.01% 4449
2025
Q1 		$20.8K Sell
13,700
-31,400
-70% -$44K ﹤0.01% 4557
2024
Q4 		$49.6K Buy
+45,100
New +$108K ﹤0.01% 4986
2024
Q2 		– Sell
-10,900
Closed -$26.1K – 4732
2024
Q1 		$26.1K Buy
+10,900
New +$20.6K ﹤0.01% 4319
2022
Q4 		– Sell
-16,900
Closed -$28K – 4329
2022
Q3 		$28K Buy
16,900
+5,500
+48% +$10.3K ﹤0.01% 4308
2022
Q2 		$14K Buy
11,400
+1,400
+14% +$2.01K ﹤0.01% 4284
2022
Q1 		$17K Buy
+10,000
New +$19.4K ﹤0.01% 5262
2021
Q3 		– Sell
-20,500
Closed -$71K – 6474
2021
Q2 		$71K Buy
20,500
+9,800
+92% +$34.9K ﹤0.01% 5527
2021
Q1 		$22K Sell
10,700
-5,600
-34% -$12.6K ﹤0.01% 5749
2020
Q4 		$37K Buy
16,300
+3,300
+25% +$8.66K ﹤0.01% 4649
2020
Q3 		$43K Buy
+13,000
New +$36.4K ﹤0.01% 4297
2020
Q2 		– Sell
-22,200
Closed -$44K – 4781
2020
Q1 		$44K Buy
+22,200
New +$54K ﹤0.01% 4298
2019
Q4 		– Sell
-10,000
Closed -$36K – 4827
2019
Q3 		$36K Sell
10,000
-3,900
-28% -$14.1K ﹤0.01% 4102
2019
Q2 		$58K Sell
13,900
-6,400
-32% -$27.7K ﹤0.01% 4162
2019
Q1 		$104K Buy
20,300
+6,800
+50% +$32.6K ﹤0.01% 4129
2018
Q4 		$51K Sell
13,500
-20,900
-61% -$99.8K ﹤0.01% 4168
2018
Q3 		$207K Sell
34,400
-1,800
-5% -$9.9K ﹤0.01% 4226
2018
Q2 		$172K Hold
36,200
– – ﹤0.01% 4475
2018
Q1 		$172K Buy
+36,200
New +$169K ﹤0.01% 4475
2017
Q4 		– Sell
-62,800
Closed -$134K – 5100
2017
Q3 		$134K Sell
62,800
-5,600
-8% -$11.1K ﹤0.01% 3974
2017
Q2 		$162K Buy
+68,400
New +$182K ﹤0.01% 3715
2016
Q4 		– Sell
-14,800
Closed -$18K – 4656
2016
Q3 		$18K Buy
+14,800
New +$26.3K ﹤0.01% 4513

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Wolverine Trading's GALT Position: Q3 2022 in Review

Wolverine Trading sold out of Galectin Therapeutics (GALT) in Q3 2022, closing a stake of 12,310 shares — an estimated $23K sold.

Wolverine Trading first reported a position in GALT in Q3 2016 and held it in 10 quarters. The position peaked at $103K in Q3 2018. 59 funds tracked by Wall St. Rank hold GALT as of Q3 2022.

  • Wolverine Trading reported no remaining Galectin Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 12,310 Galectin Therapeutics shares in Q3 2022, an estimated $23K.
  • Wolverine Trading first reported a position in Galectin Therapeutics in Q3 2016 and held it in 10 quarters.
  • Wolverine Trading's Galectin Therapeutics position peaked at $103K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.